Merit Medical Systems, Inc. (MMSI) Can’t Burn Your Long Portfolio. Just Reaches 52-Week High

May 17, 2018 - By Bradley Stiles

Merit Medical Systems, Inc. (NASDAQ:MMSI) Logo

Investors sentiment decreased to 1 in Q4 2017. Its down 0.28, from 1.28 in 2017Q3. It dropped, as 29 investors sold Merit Medical Systems, Inc. shares while 69 reduced holdings. 29 funds opened positions while 69 raised stakes. 45.18 million shares or 1.94% more from 44.33 million shares in 2017Q3 were reported.
15,399 were accumulated by Blair William & Il. Ftb Advisors reported 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Riverhead Cap Lc reported 7,220 shares. Dalton Greiner Hartman Maher & holds 0.85% or 374,052 shares in its portfolio. Frontier Cap Mngmt Com Ltd Com holds 0.19% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 587,376 shares. Perceptive Advsr Ltd Liability Corporation owns 874,013 shares. Rhumbline Advisers invested in 0.01% or 111,217 shares. Cubist Systematic Strategies has 0.03% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI). Panagora Asset Mngmt has 3,365 shares. Comml Bank Of Montreal Can holds 48,561 shares. California State Teachers Retirement System stated it has 76,725 shares or 0.01% of all its holdings. Hbk Invests Ltd Partnership has invested 0.01% in Merit Medical Systems, Inc. (NASDAQ:MMSI). Moreover, Dimensional Fund Advsr L P has 0.04% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI). Thrivent Financial For Lutherans holds 31,200 shares or 0% of its portfolio. Rothschild Asset Incorporated holds 0.3% or 654,960 shares.

Since December 15, 2017, it had 0 insider buys, and 1 sale for $407,782 activity.

The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) hit a new 52-week high and has $56.01 target or 7.00 % above today’s $52.35 share price. The 8 months bullish chart indicates low risk for the $2.64B company. The 1-year high was reported on May, 17 by Barchart.com. If the $56.01 price target is reached, the company will be worth $184.73 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.67% or $0.35 during the last trading session, reaching $52.35. About 163,890 shares traded. Merit Medical Systems, Inc. (NASDAQ:MMSI) has risen 52.36% since May 17, 2017 and is uptrending. It has outperformed by 40.81% the S&P500.

Analysts await Merit Medical Systems, Inc. (NASDAQ:MMSI) to report earnings on July, 25. They expect $0.40 EPS, up 11.11 % or $0.04 from last year’s $0.36 per share. MMSI’s profit will be $20.16M for 32.72 P/E if the $0.40 EPS becomes a reality. After $0.31 actual EPS reported by Merit Medical Systems, Inc. for the previous quarter, Wall Street now forecasts 29.03 % EPS growth.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Ratings Coverage

Among 7 analysts covering Merit Medical Systems (NASDAQ:MMSI), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical Systems had 10 analyst reports since November 30, 2017 according to SRatingsIntel. Needham maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) rating on Thursday, April 26. Needham has “Buy” rating and $5400 target. On Thursday, April 26 the stock rating was maintained by Canaccord Genuity with “Buy”. The company was maintained on Tuesday, January 2 by Canaccord Genuity. Canaccord Genuity maintained the shares of MMSI in report on Thursday, March 1 with “Buy” rating. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) has “Buy” rating given on Wednesday, February 28 by Piper Jaffray. On Thursday, November 30 the stock rating was maintained by Wells Fargo with “Buy”. The rating was initiated by Needham with “Buy” on Thursday, April 19. The stock of Merit Medical Systems, Inc. (NASDAQ:MMSI) has “Buy” rating given on Tuesday, March 6 by SunTrust. Raymond James maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) on Thursday, April 26 with “Outperform” rating. Barrington Research upgraded the stock to “Outperform” rating in Thursday, March 1 report.

More notable recent Merit Medical Systems, Inc. (NASDAQ:MMSI) news were published by: Globenewswire.com which released: “Merit Medical to Present at Three Conferences in May” on April 30, 2018, also Seekingalpha.com with their article: “Merit Medical Systems’ (MMSI) CEO Fred Lampropoulos on Q1 2018 Results – Earnings Call Transcript” published on April 26, 2018, Globenewswire.com published: “Merit Medical Reports Record Revenues for First Quarter of 2018” on April 25, 2018. More interesting news about Merit Medical Systems, Inc. (NASDAQ:MMSI) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” published on May 11, 2018 as well as Globenewswire.com‘s news article titled: “New Research Coverage Highlights Erie Indemnity, Merit Medical, Destination Maternity, Perry Ellis International …” with publication date: May 03, 2018.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $2.64 billion. The companyÂ’s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 95.18 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: